Journal of Neurology

, Volume 260, Issue 12, pp 3030–3038

Intravenous amantadine on freezing of gait in Parkinson’s disease: a randomized controlled trial

Authors

  • Jee Young Lee
    • Department of Neurology, Seoul National University-Seoul Metropolitan Government Boramae Medical CenterCollege of Medicine Seoul National University
  • Sohee Oh
    • Department of Biostatistics, Seoul National University-Seoul Metropolitan Government Boramae Medical CenterCollege of Medicine Seoul National University
  • Jong Min Kim
    • Department of Neurology, Seoul National University Bundang HospitalCollege of Medicine Seoul National University
  • Ji Sun Kim
    • Department of Neurology, Samsung Medical Center, College of Medicine Sungkyunkwan UniversitySungkyunkwan University School of Medicine
  • Eungseok Oh
    • Department of Neurology, Seoul National University Bundang HospitalCollege of Medicine Seoul National University
  • Hee-Tae Kim
    • Department of Neurology, Hanyang University Medical centerCollege of Medicine Hanyang University
  • Beom S. Jeon
    • Department of Neurology and Movement Disorders Center, Seoul National University HospitalCollege of Medicine Seoul National University
    • Department of Neurology, Samsung Medical Center, College of Medicine Sungkyunkwan UniversitySungkyunkwan University School of Medicine
Original Communication

DOI: 10.1007/s00415-013-7108-7

Cite this article as:
Lee, J.Y., Oh, S., Kim, J.M. et al. J Neurol (2013) 260: 3030. doi:10.1007/s00415-013-7108-7

Abstract

To compare the effects of intravenous amantadine and placebo therapy on freezing of gait in patients with Parkinson’s disease, this randomized, double-blind, placebo-controlled, multicenter trial compared the efficacy of 5 days intravenous amantadine and placebo treatments on freezing of gait in 42 subjects randomly allocated 2:1 to amantadine or placebo groups. Changes in freezing of gait questionnaire (FOG-Q) scores and in unified Parkinson’s disease rating scale (UPDRS) scores, from baseline to immediately (V1) and 1 month (V2) after treatments, were assessed. Among the 42 patients (amantadine n = 29, placebo n = 13, a mean age 65.5 ± 9.4 years and a mean FOG-Q score 17.4 ± 3.2), 40 subjects completed treatment. There was no significant group difference on the primary outcome measure as total FOG-Q score changes at V1. However a significant beneficial effect of amantadine on freezing was seen at V2 in the UPDRS Part II freezing and FOG-Q item 3 scores, and there was significant improvement in the UPDRS Part IV total score and in the UPDRS Part II getting out of bed score in the amantadine group at both V1 and V2. There was no serious adverse event reported during the study. The intravenous amantadine therapy did not show a significant improvement on overall FOG-Q scores in patients with moderate-to-severe freezing; however, it might be beneficial by attenuating freezing severity and improving patients’ mobility. To prove this finding further studies with larger sample sizes are warranted in the future.

Keywords

Freezing of gait Parkinson’s disease Intravenous amantadine Randomized-controlled trial

Supplementary material

415_2013_7108_MOESM1_ESM.docx (19 kb)
Supplementary material 1 (DOCX 18 kb)
415_2013_7108_MOESM2_ESM.docx (20 kb)
Supplementary material 2 (DOCX 20 kb)

Copyright information

© Springer-Verlag Berlin Heidelberg 2013